Spearheading Frontier For Future Generation.
Science, Technology and Research Development
At a time when pharmaceutical and biotechnology businesses around the world are grappling with declining R&D productivity, Singapore’s integrated research ecosystem enables companies to access multidisciplinary capabilities in a single location, which improves R&D decision-making and accelerates drug discovery and development. Representing a thriving sector of Singapore’s economic growth, the biopharmaceutical sector contributed about S$22.8 billion in output and over 6,000 jobs in 2011. Compared to 2010, the biopharmaceutical sector expanded by more than 30% in 2011.
Today, Singapore is recognised as a ‘Global Hydrohub’ with more than 70 companies in a vibrant water industry ecosystem. With a growing global emphasis on water and the environment, Singapore is well positioned to take the lead in this industry as an R&D base and provider of water solutions. In July 2006, the government committed S$330 million to fund R&D and manpower development in the water industry. The water sector alone should see its value-added contribution to the GDP rise from S$0.5 billion in 2003 to S$1.7 billion in 2015.
Did you know?
- According to Datamonitor, Singapore was the third fastest growing nation globally in the export of pharmaceutical goods from 2000 to 2010.
- Within four decades, Singapore has transformed its vulnerability in water into its strength with the development of major national water projects such as NEWater, the Deep Tunnel Sewerage System and the Marina Barrage.
- The city-state has also over the years established a diversified and sustainable water supply from four different sources known as the Four National Taps (water from local catchment areas, imported water, reclaimed water known as NEWater and desalinated water).
Hyflux Ltd
http://www.hyflux.comSGX-listed Hyflux Ltd is a leading fully-integrated water solutions company and among the top global desalination plant providers. Hyflux offers innovative, cost-effective and sustainable solutions in seawater desalination, water recycling, wastewater treatment and membrane bioreactor, and potable water treatment.
Hyflux has a strong R&D focus on membrane and materials technologies. Hyflux’s membrane products and systems have been installed in more than 1,000 plants worldwide, including China’s largest seawater reverse osmosis (SWRO) desalination plant in Tianjin and the world’s largest SWRO desalination plant in Algeria. Hyflux’s track record also includes Singapore’s first NEWater plant and first SWRO desalination plant. The Company is currently developing Singapore’s second SWRO plant.
Founded in 1989, Hyflux today employs about 2,300 staff worldwide and has projects and operations across Southeast Asia, China, India, Europe, and the Middle East & North Africa region. Its membrane products and systems are also sold to Latin America.
The Hyflux team is a global, diverse and passionate group. The diversity of talents, experiences and perspectives serve as catalysts for new ideas and innovation. Hyflux believes in creating an inclusive workplace where employees are given unparalleled opportunities to develop their potential through learning and development programmes, job rotation and overseas postings.
- Engineering (Bioengineering / Chemical / Civil / Electrical / Environmental / Mechanical)
Novartis Singapore Pharmaceutical Manufacturing
http://www.novartis.comNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 131,000 full-time-equivalent associates and operate in more than 140 countries around the world.
Singapore is a strategic hub for Novartis. Novartis currently employs approximately 1,200 full-time equivalent associates in Singapore, and this will expand to 1,600 by year 2018.
Novartis associates are provided with lifelong learning and development opportunities so as to advance personally and professionally together with the flexibility to explore and implement ideas in a lean organization, with empowered and highly skilled associates and cross-functional insights.
Scholars will be exposed to a Process Oriented Organization culture that focuses on accountability, empowerment, being self-directed and practicing informal leadership skills. Other opportunities would be through innovative and collaborative projects that build depth of experience and networking opportunities to enhance their outlook on different career paths available.
- Engineering (Chemical / Electrical / Electronic / Mechanical Design & Manufacturing / Mechanical)
- Information and Communication Technology (Computing / Computer Science / Information System / Information Technology)
- Pharmacy
- Science (Applied Chemistry / Biotechnology / Chemistry)
